Compounds / Cognitive / Semax

Semax

Semax (ACTH 4-10 Analog: Met-Glu-His-Phe-Pro-Gly-Pro)
CognitiveWell ResearchedFDA: Not approved (registered in...

Overview

Registered drug in Russia/Ukraine. Human trials: cognitive/neuroprotective post-stroke and in attention/memory tasks. Intranasal primary clinical route. Limited Western RCT data.

Mechanism of Action

ACTH 4-10 analog. No glucocorticoid activity. Upregulates BDNF synthesis and release. Enhances dopamine/serotonin signaling. Neuroprotective via proinflammatory cytokine inhibition.

Pharmacokinetics

Half-life
3 min
Peak (Tmax)
20 min
Cleared
~15 min

Molecular Profile

Molecular weight
835.1 Da
CAS number
80714-61-0

Key Research Findings

BDNF upregulation; neuroprotection post-stroke; cognitive enhancement; registered Russian drug.

Published Research

J Neurochem
Dolotov OV et al. Semax: An ACTH-Derived Peptide with Neuroprotective Effects
View source
Zh Nevrol Psikhiatr (2018)
Gusev EI et al. Efficacy of Semax in treatment at different stages of ischemic stroke
View source

Related Cognitive Compounds

NA Semax AmidateSelankAdalankAdamaxDihexaCerebrolysin
Clinical Guidance

Research data is not a treatment plan. If you are considering Semax, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Semax? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals